Open AccessCardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Author(s) -
Timothy Reid
Publication year - 2021
Publication title -
the journal of family practice
Language(s) - English
Resource type - Journals
eISSN - 1533-7294
DOI - 10.12788/jfp.0216
Subject(s) - medicine , guideline , intensive care medicine , diabetes mellitus , canagliflozin , kidney disease , type 2 diabetes mellitus , clinical trial , type 2 diabetes , heart failure , clinical practice , incidence (geometry) , empagliflozin , disease , endocrinology , physical therapy , pathology , physics , optics
At the end of the activity, participants will be able to:• Identify how heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) and associated cardiovascular (CV) risks are interconnected.• Initiate guideline-recommended therapy to reduce CV risk in patients with HF, CKD, and/or T2DM.• Apply evidence for sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) to clinical practice, based on recent and emerging trials.• Review evidence suggesting increased incidence and severity of COVID-19 infection in patients with diabetes.